

Amendments to the Claims:

This following listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Cancelled)
2. (Currently Amended) ~~The delivery system of claim 1,~~ A pharmaceutical composition comprising wherein said reverse micelle comprises at least one or more than one amphipathic ionic compound in monomeric form, and said polar agent of interest comprises at least one or more than one polar ionizable agent of interest, wherein a reverse micelle comprising the one, or more than one amphipathic ionic compound and the one, or more than one polar ionizable agent of interest is formed after the pharmaceutical composition is contacted with an aqueous fluid.
3. (Currently Amended) ~~The delivery system~~ pharmaceutical composition of claim 2, wherein said amphipathic ionic compound is comprises an anionic surfactant capable of forming reverse micelles in a fluid environment.
4. (Currently Amended) ~~The delivery system~~ pharmaceutical composition of claim 2, wherein said amphipathic ionic compound is comprises a cationic surfactant capable of forming reverse micelles in a fluid environment.
5. (Currently Amended) ~~The delivery system~~ pharmaceutical composition of claim 2, wherein said agent of interest is characterized by has a partition coefficient between water and octanol at pH 7.4 of less than about 10.
6. (Currently Amended) ~~The delivery system~~ pharmaceutical composition of claim 2, wherein said amphipathic ionic compound is present in an amount of about 0.5 weight % to about 500 weight %.

7. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 2, wherein said agent ~~of interest is comprises~~ comprises a therapeutically active compound of a Class III ~~biopharmaceutics classification and exhibits high solubility and low permeability~~ biopharmaceutical.
8. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 2, wherein the agent of interest comprises a plurality of discrete active particulates.
9. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 2, wherein said amphipathic ionic compound is an ionic surfactant or mixture of ionic surfactants selected from the group consisting of anionic surfactants, cationic surfactants and zwitterionic surfactants.
10. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 9, wherein the anionic ~~surfactants are~~ surfactant is selected from the group consisting of sodium dodecyl sulfate, ~~or~~ potassium dodecyl sulfate, sodium octadecylsulfate, sodium bis(2-ethylhexyl) sulfosuccinate (AOT), and a combination thereof.
11. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 9, wherein the cationic ~~surfactants are~~ surfactant is selected from the group ~~consisting~~ consisting of didodecyl dimethyl ammonium bromide (DDAB), cetyl-triammonium ~~amide~~ bromide (CTAB), cetylpyridinium bromide (CPB), dodecyl trimethyl ammonium chloride (DOTAC), sodium perfluorononanoate (SPFN), hexadecyl trimethyl ammonium bromide (HDTMA), or a combination thereof.
12. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 9, formulated ~~into~~ as a solid tablet, a matrix tablet, granules or a capsule.
13. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 9, further comprising one or more than one pharmaceutically acceptable ~~excipients~~ excipient.

14. (Cancelled)

15. (Cancelled)

16. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 9, wherein the ~~system is derived from~~ pharmaceutical composition is in the form of one of a matrix-type matrix solid compact, made by a compression or pelletization method, ~~or a matrix-type and a matrix~~ extrusion spheroid, made by a wet or dry extrusion method.

17. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 9, wherein ~~said system~~ the pharmaceutical composition is granulated or microencapsulated to form particulates that may be compressed into solid compacts or filled into capsules.

18. (Currently Amended) The ~~delivery system~~ pharmaceutical composition of claim 9, wherein the pharmaceutical composition is in a said dosage form is selected from the group consisting of granulated, particulate, spheroidal, compact and dry blends, and wherein ~~said system~~ the pharmaceutical composition can be filled into capsules or suspended in a suitable liquid vehicle.

19. (Cancelled)

20. (Currently Amended) A method of delivering a therapeutic agent to a subject in need thereof, comprising:[[.]]

i) formulating the ~~delivery system~~ pharmaceutical composition of claim 2, ~~such wherein~~ that the agent of interest comprises a therapeutic agent, and[[;]]

ii) administering said ~~delivery system~~ pharmaceutical composition to a subject in need thereof.

21. (Original) The method of claim 20, wherein said administering comprises oral administration.

22. (New) The pharmaceutical composition of claim 2, wherein the at least one amphipathic ionic compound and the at least one polar ionizable agent of interest are oppositely charged.

23. (New) The pharmaceutical composition of claim 13, wherein said one, or more than one pharmaceutically acceptable excipient is one, or more than one compound selected from the group consisting of: one, or more than one viscosity enhancer; one, or more than one enteric polymer; one, or more than one pH-specific barrier polymer; one, or more than one diluent; one, or more than one anti-adherent; one, or more than one glidant; one, or more than one binder; one, or more than one solubilizer; one, or more than one channeling agent; one, or more than one wetting agent; one, or more than one buffering agent; one, or more than one flavourant; one, or more than one adsorbent; one, or more than one sweetening agent; one, or more than one colorant; one, or more than one lubricant; and a combination thereof.

24. (New) The pharmaceutical composition of claim 2, wherein the one, or more than one agent of interest is one, or more than one compound selected from the group consisting of one, or more than one analgesic; one, or more than one anti-inflammatory; one, or more than one antimicrobial; one, or more than one amoebicidal; one, or more than one trichomonocidal agent; one, or more than one anti-Parkinson; one, or more than one anti-malarial; one, or more than one anticonvulsant; one, or more than one anti-depressant; one, or more than one anti-arthritic; one, or more than one anti-fungal; one, or more than one antihypertensive; one, or more than one antipyretic; one, or more than one anti-parasite; one, or more than one antihistamine; one, or more than one alpha-adrenergic agonist; one, or more than one alpha blocker; one, or more than one anaesthetic; one, or more than one bronchial dilator; one, or more than one biocide; one, or more than one bactericide; one, or more than one bacteriostat; one, or more than one beta adrenergic blocker; one, or more than one calcium channel blocker; one, or more than one cardiovascular drug; one, or more than one contraceptive; one, or more than one decongestant; one, or more than one diuretic; one, or more than one depressant; one, or more than one diagnostic; one, or more than one electrolyte; one, or more than one hypnotic; one, or more than one hormone; one, or more than one hyperglycaemic; one, or more than one muscle relaxant; one, or more than one muscle contractant; one, or more than one ophthalmic; one, or more than one parasympathomimetic; one, or more than one psychic energizer; one, or more than one

sedative; one, or more than one sympathomimetic; one, or more than one tranquilizer; one, or more than one viricide; one, or more than one vitamin; one, or more than one non-steroidal anti-inflammatory; one, or more than one angiotensin converting enzyme inhibitor; one, or more than one polypeptide; one, or more than one protein; one, or more than one sleep inducer; and a combination thereof.